Berliner Boersenzeitung - 'Ray of hope': New advances in fighting a range of cancers

EUR -
AED 3.862042
AFN 71.804229
ALL 98.797466
AMD 410.848078
ANG 1.899611
AOA 958.940084
ARS 1058.238507
AUD 1.620225
AWG 1.892645
AZN 1.789395
BAM 1.967098
BBD 2.128123
BDT 125.953443
BGN 1.956332
BHD 0.396362
BIF 3113.654377
BMD 1.051469
BND 1.420345
BOB 7.309987
BRL 6.106303
BSD 1.054054
BTN 88.858242
BWP 14.398702
BYN 3.449312
BYR 20608.799376
BZD 2.124603
CAD 1.482114
CDF 3017.717361
CHF 0.931823
CLF 0.037163
CLP 1025.434617
CNY 7.631781
CNH 7.633625
COP 4610.430258
CRC 537.123794
CUC 1.051469
CUP 27.863938
CVE 110.899869
CZK 25.280471
DJF 187.688029
DKK 7.458945
DOP 63.517579
DZD 140.586407
EGP 52.170119
ERN 15.77204
ETB 131.427132
FJD 2.391409
FKP 0.829943
GBP 0.835835
GEL 2.870265
GGP 0.829943
GHS 16.600348
GIP 0.829943
GMD 74.654183
GNF 9083.084398
GTQ 8.138513
GYD 220.516588
HKD 8.183129
HNL 26.634729
HRK 7.500403
HTG 138.343291
HUF 410.963645
IDR 16706.744023
ILS 3.829478
IMP 0.829943
INR 88.660528
IQD 1380.730543
IRR 44253.716178
ISK 145.081723
JEP 0.829943
JMD 167.279216
JOD 0.745807
JPY 161.530937
KES 136.168674
KGS 91.27086
KHR 4230.257223
KMF 493.08668
KPW 946.322022
KRW 1469.239507
KWD 0.323541
KYD 0.878345
KZT 526.313
LAK 23147.955604
LBP 94386.027846
LKR 306.711669
LRD 189.714255
LSL 19.056857
LTL 3.104715
LVL 0.636023
LYD 5.15863
MAD 10.589624
MDL 19.267668
MGA 4925.289533
MKD 61.559552
MMK 3415.131453
MNT 3572.892815
MOP 8.446615
MRU 41.912953
MUR 49.755948
MVR 16.245234
MWK 1827.697802
MXN 21.562203
MYR 4.686928
MZN 67.1904
NAD 19.056857
NGN 1769.759472
NIO 38.782387
NOK 11.685421
NPR 142.17627
NZD 1.797046
OMR 0.404805
PAB 1.054054
PEN 3.992029
PGK 4.245903
PHP 62.029854
PKR 292.749574
PLN 4.308154
PYG 8212.168477
QAR 3.845012
RON 4.976502
RSD 117.004332
RUB 110.908439
RWF 1439.152416
SAR 3.949844
SBD 8.822449
SCR 14.320848
SDG 632.459485
SEK 11.526107
SGD 1.415456
SHP 0.829943
SLE 23.868157
SLL 22048.791639
SOS 602.35403
SRD 37.320818
STD 21763.29276
SVC 9.222974
SYP 2641.848152
SZL 19.051426
THB 36.453918
TJS 11.235312
TMT 3.690657
TND 3.343207
TOP 2.462647
TRY 36.425338
TTD 7.15912
TWD 34.112826
TZS 2781.137122
UAH 43.741741
UGX 3905.431745
USD 1.051469
UYU 44.926765
UZS 13521.66479
VES 48.905782
VND 26723.093681
VUV 124.832555
WST 2.935272
XAF 659.740094
XAG 0.034439
XAU 0.0004
XCD 2.841648
XDR 0.806231
XOF 659.746405
XPF 119.331742
YER 262.78845
ZAR 19.031706
ZMK 9464.475804
ZMW 29.063935
ZWL 338.572704
  • RBGPF

    0.8100

    61

    +1.33%

  • RYCEF

    0.0200

    6.79

    +0.29%

  • CMSC

    0.0578

    24.73

    +0.23%

  • AZN

    0.7700

    66.4

    +1.16%

  • VOD

    0.1800

    8.91

    +2.02%

  • GSK

    0.1900

    34.15

    +0.56%

  • NGG

    0.1500

    63.26

    +0.24%

  • SCS

    0.4500

    13.72

    +3.28%

  • RIO

    0.6300

    62.98

    +1%

  • BTI

    -0.0500

    37.33

    -0.13%

  • RELX

    -0.1800

    46.57

    -0.39%

  • CMSD

    0.1200

    24.58

    +0.49%

  • BP

    -0.4000

    29.32

    -1.36%

  • BCC

    8.7200

    152.5

    +5.72%

  • BCE

    0.2500

    27.02

    +0.93%

  • JRI

    0.1600

    13.37

    +1.2%

'Ray of hope': New advances in fighting a range of cancers
'Ray of hope': New advances in fighting a range of cancers / Photo: SAUL LOEB - AFP/File

'Ray of hope': New advances in fighting a range of cancers

New advances in the fight against a range of cancers have been revealed at the annual meeting of the American Society of Clinical Oncology (ASCO), which wraps up in Chicago on Tuesday.

Text size:

Here are some of the announcements that have most excited experts.

- Lung cancer -

One of the trial results that caused a stir in Chicago has raised hopes for a new weapon against lung cancer, the deadliest of all cancers.

The treatment osimertinib was shown to halve the risk of death from a certain type of lung cancer when taken daily after surgery to remove the tumour.

Developed by the pharmaceutical group AstraZeneca, the daily pill targets patients with non-small cell cancer -- by far the most common type -- as well as a mutation of their epidermal growth factor receptor, or EGFR.

Iris Pauporte, head of research at France's League Against Cancer, told AFP the advance was a "big ray of hope" for this type of cancer, for which progress has been slow.

Muriel Dahan, head of research at Unicancer, said that if the results are confirmed, it "should change" common practice in treating this kind of lung cancer.

Systematic testing for the EGFR mutation would also become necessary for lung cancer patients, she added.

- Brain cancer -

Another treatment, called vorasidenib, was found to significantly prolong the progression-free survival of patients with brain tumour glioma, according to clinical trial results.

The daily pill, developed by French pharma firm Servier, aims to block an enzyme responsible for the progression of some brain cancers, which have been particularly difficult to treat.

Patrick Therasse, Servier's vice-president of oncology research, told AFP that there "have been few therapeutic advances for brain tumours over the last 20 years".

"Thanks to our targeted treatment, patients avoided cancer progression for 27.7 months, compared to 11.1 months" for those taking a placebo, he added.

Fabrice Andre, head of research at France's Gustave Roussy cancer centre, said "precision medicine opens a door for a disease for which there was nothing until now".

"It means that science can unblock situations that were catastrophic," he told AFP.

Unicancer's Dahan said it was important to "remain cautious" but added that "this could become the new therapeutic standard -- depending on further trials".

- Breast cancer -

Preliminary trial results also released in Chicago indicated the drug ribociclib reduced the risk of breast cancer recurring by 25 percent for a large group of early-stage survivors.

The drug, developed by Swiss pharmaceutical maker Novartis, is already widely approved around the world. It was tested in combination with hormonal therapy.

ASCO expert Rita Nanda said it was a "very important and practice-changing clinical trial".

- Cervical cancer -

There was also good news for patients with early-stage cervical cancer with a low risk of progression.

There was no greater risk of the cancer returning for patients who get a simple hysterectomy, in which the uterus and cervix are removed, than a radical hysterectomy, in which the uppermost part of the vagina is also removed, according to phase three trials.

League Against Cancer's Pauporte said this was "good news," adding that "it shows that it's not just progress involving drugs that was important".

- Ovarian cancer -

A trial also presented at ASCO showed that taking the antibody treatment mirvetuximab soravtansine significantly improved the survival rate of patients with ovarian cancer, a particularly deadly form of cancer.

ASCO expert Merry Jennifer Markham said the treatment "demonstrates progress and offers hope for these patients".

- Rectal cancer -

Study results released in Chicago indicated that patients with locally advanced rectal cancer could receive chemotherapy without getting radiation therapy before undergoing surgery.

This would spare patients from the brutal side effects of radiation.

- Vaccines -

Vaccines that treat existing cancer have long been a goal of the medical community.

Preliminary studies announced at the ASCO meeting involved vaccines targeting lung cancer, head and neck cancers, brain tumour glioblastoma and the cancer-causing HPV virus.

Christophe Le Tourneau, an oncologist at France's Curie Institute which presented a study about a vaccine for a certain form of HPV, said there has been "significant technological progress" in the area recently.

"Therapeutic vaccines, we talk about them more and more, and there are more and more trials in progress," he said.

(A.Lehmann--BBZ)